Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: A subanalysis of the EPIC study of deferasirox
Authors: Vip Viprakasit
Hishamshah Ibrahim
Shau Yin Ha
Phoebe Joy Ho
Chi Kong Li
Lee Lee Chan
Chang Fang Chiu
Pranee Sutcharitchan
Dany Habr
Gabor Domokos
Bernard Roubert
Hong Ling Xue
Donald K. Bowden
Kai Hsin Lin
Mahidol University
Kuala Lumpur Hospital
The University of Hong Kong
Royal Prince Alfred Hospital
Prince of Wales Hospital Hong Kong
University of Malaya Medical Centre
China Medical University Hospital Taichung
Chulalongkorn University
Novartis Pharmaceuticals Corporation
Novartis International AG
Novartis Asia Pacific Pharmaceuticals Pte Ltd
Monash Medical Centre
National Taiwan University Hospital
Keywords: Medicine
Issue Date: 1-Mar-2011
Citation: International Journal of Hematology. Vol.93, No.3 (2011), 319-328
Abstract: Although thalassaemia is highly prevalent in the Asia-Pacific region, clinical data on efficacy and safety profiles of deferasirox in patients from this region are rather limited. Recently, data from the multicentre Evaluation of Patients' Iron Chelation with Exjade (EPIC) study in 1744 patients with different anaemias has provided an opportunity to analyse 1115 thalassaemia patients, of whom 444 patients were from five countries in the Asia-Pacific region (AP) for whom thalassaemia management and choice of iron chelators were similar. Compared to the rest of the world (ROW), baseline clinical data showed that the AP group appeared to be more loaded with iron (3745.0 vs. 2822.0 ng/ml) and had a higher proportion on deferoxamine monotherapy prior to the study (82.9 vs. 58.9%). Using a starting deferasirox dose based on transfusional iron intake and tailoring it to individual patient response, clinical efficacy based on serum ferritin reduction in AP and ROW thalassaemia patients was similar. Interestingly, the AP group developed a higher incidence of drug-related skin rash compared to ROW (18.0 vs. 7.2%), which may indicate different pharmacogenetic backgrounds in the two populations. Our analysis confirms that, with appropriate adjustment of dose, deferasirox can be clinically effective across different regions, with manageable side effects. © The Japanese Society of Hematology 2011.
ISSN: 09255710
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.